Actively Recruiting
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Led by Sun Yat-sen University · Updated on 2025-12-08
12
Participants Needed
2
Research Sites
91 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
W
Westlake Therapeutics
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a single-arm, open-label, investigator-initiated clinical study (IIT) designed to evaluate the preliminary efficacy, safety, tolerability, immunogenicity, and pharmacokinetic (PK) characteristics of WTX212A Injection in patients with advanced solid tumors.
CONDITIONS
Official Title
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily signed informed consent and willingness to complete all study procedures
- Male or female aged 18 to 75 years (inclusive)
- Histologically or cytologically confirmed advanced malignant tumors
You will not qualify if you...
- Serious uncontrolled internal diseases such as uncontrolled diabetes, active peptic ulcer, liver cirrhosis, or severe cardiovascular diseases including NYHA Class II or higher heart failure, unstable angina, recent myocardial infarction within 6 months, or difficult-to-control high blood pressure
- Uncontrollable pleural, peritoneal, or pericardial effusion requiring drainage or recurring after drainage
- History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or severe lung function impairment
- Previous immune-oncology drug treatment causing adverse events that led to permanent discontinuation of such treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Cancer Center of SUN YAT-senU
Guangzhou, Guangdong, China, 510000
Actively Recruiting
2
Cancer center of Sun Yat-sen University
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
R
RuiHua Xu, PhD
CONTACT
H
Huiyan Luo, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here